

# RYAN MCKAY RICH, MD

RETINA CONSULTANTS OF SOUTHERN COLORADO, P.C.  
3030 N CIRCLE DRIVE SUITE 301  
COLORADO SPRINGS, CO 80909  
(719) 473-9595  
[WWW.COLORADORETINA.COM](http://WWW.COLORADORETINA.COM)

## EDUCATION AND TRAINING

---

07/07/2006 – 07/06/2008 <i>Fellowship in Vitreoretinal Surgery</i>	Bascom Palmer Eye Institute, Miami, FL
07/07/2005-07/06/2006 <i>Fellowship in Medical Retina</i>	Bascom Palmer Eye Institute, Miami, FL
07/2002–06/2005 <i>Residency in Ophthalmology</i>	Saint Louis University, St. Louis, MO
07/2001-06/2002 <i>Internship/Transitional Year</i>	Forest Park Hospital, St. Louis, MO
07/1997–05/2001 <i>Doctor of Medicine</i>	Saint Louis University, St. Louis, MO
08/1990–04/1997 <i>B.S., Zoology</i>	Brigham Young University, Provo, UT

---

## CERTIFICATION AND LICENSURE

---

Diplomate, American Board of Ophthalmology (2007)  
Medical License, State of Florida (2005 present)  
Medical License, State of Colorado (2008 present)

---

## AWARDS AND HONORS

---

Saint Louis University, St. Louis, MO

- Chief Resident, 2004-2005
- Resident of the Year, 2004-2005
- Resident Research Award, 2004-2005
- Roya Rabbani Award, 2004 – Excellence in Patient Care

Brigham Young University, Provo, UT

- Summer Research Fellowship Award, 1998

- Cum Laude, Dean's List, Academic Scholarship

---

## RESEARCH

---

### PUBLICATIONS

**Rich RM**, Berrocal AM, Murray TG. Treatment of Best's disease-associated choroidal neovascularization in children. *Journal of Pediatric Ophthalmology and Strabismus*. 2008 (in press).

Punjabi OS, **Rich RM**, Davis JL, Gregori G, Flynn HW Jr, Lujan BJ, Rosenfeld PJ, Puliafito CA. Imaging serpiginous choroidopathy with spectral domain optical coherence tomography. *Ophthalmic Surg Lasers Imaging*. 2008 Jul-Aug;39(4 Suppl):S95-8.

**Rich RM**, Smiddy WE, Davis JD. Infectious scleritis after retinal surgery. *American Journal of Ophthalmology*. 2008 Apr;145(4):695-9.

**Rich RM**. Retinal Degenerations: Imaging, Research, and Trials. *Retinal Physician*. 2008 Apr:58-63.

**Rich RM**, Puliafito CA, Rosenfeld PJ. Diagnosis and treatment of neovascular age-related macular degeneration. *Contemporary Ophthalmology*, Dec 2007, 6(23):1-8.

Vasconcelos-Santos DV, Nehemy MB, **Rich RM**, Negrao S, Flynn HW Jr. Intravitreal triamcinolone acetate: potential complications. *Expert Rev. Ophthalmol*. Dec 2007, 2(6), 987-1000.

Rosenfeld PJ, **Rich RM**, Lalwani GA. Ranibizumab: Phase III clinical trial results. *Ophthalmology Clinics of North America*. Sep 2006, 19(3):361-72.

**Rich RM**, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. *Retina*. May 2006, 26(5):495-511.

### PRESENTATIONS/ POSTERS

Vick VL, Holds JB, Hartstein ME, **Rich RM**, Davidson BR. Use of autologous platelet concentrate in blepharoplasty surgery. *Ophthalmic Plastic & Reconstructive Surgery*. Mar 2006, 22(2):102-4.

**Rich RM**, Berrocal AM, Parel JM, Tutiven et al. The Bascom Palmer Eye Institute Pediatric OCT System - Our Initial Experience. Association for Research in Vision and Ophthalmology, May 2005; Fort Lauderdale, Florida.

**Rich RM**, Cruz OA. "Ophthalmologic findings in nevoid basal cell carcinoma syndrome." American Academy of Ophthalmology, November

2006; Las Vegas, Nevada.

**Rich RM**, Smetana S, Akduman L. “Comparison of intravitreal and sub-Tenon’s triamcinolone acetate injections for pseudophakic cystoid macular edema.” American Academy of Ophthalmology, October 2005; Chicago, Illinois.

**Rich RM** and Akduman L. “Long-term results of successful limited macular translocation subfoveal choroidal neovascular membranes.” Saint Louis University Resident and Alumni Day, June 2004.

Akduman L, Amato J, **Rich RM**. “25 gauge pars plana vitrectomy – indications and complications.” Mediterranean Retina Meeting, June 2004.

**Rich RM**, Hartstein MA, Mohadjer J. “Development of conjunctival MALT-type lymphoma in a patient with systemic sarcoidosis.” American Society of Ophthalmic Plastic and Reconstructive Surgery, November 2004; New Orleans, Louisiana.

**Rich RM**, et al. “A retrospective review of subnormal or non-response to Xalatan in glaucomatous eyes.” American Glaucoma Society Annual Meeting, March 2001; Newport Beach, California

CLINICAL  
STUDIES

EYETECH (EOP1004)	A Phase II/III randomized, double-masked, controlled, dose-ranging, multi-center comparative trial, in parallel groups, to establish the safety and efficacy of intravitreal injections of EYE001 (Anti-VEGF Pegylated Aptamer) given every 6 weeks for 54 weeks in patients with exudative Age-Related Macular Degeneration (AMD) <b>Sponsor: Eyetech Pharmaceuticals, Inc &amp; Pfizer Inc.</b>
EYETECH (EOP1006)	A randomized, double-masked, multi-center trial of the safety, tolerability and pharmacokinetics of 1mg/eye and 3mg/eye intravitreal injections of EYE001 (Anti-VEGF Pegylated Aptamer) given every 6 weeks for 54 weeks in patients with exudative Age-Related Macular Degeneration (AMD) <b>Sponsor: Eyetech Pharmaceuticals, Inc &amp; Pfizer Inc.</b>
ALCON (C-02-60)	(AART) An Evaluation of Efficacy and Safety of Posterior Juxtasclear Administrations of Anecortave Acetate for Depot Suspension (15 mg or 30 mg)

Versus Sham Administration in Patients (Enrolled in Study "A" or Study "B" ) at Risk for Developing Sight-Threatening Choroidal Neovascularization (CNV) Due to Exudative Age Related Macular Degeneration (AMD)

**Sponsor: Alcon Research, Ltd.**

GENENTECH(FVF2508g)

An extension study to evaluate the safety and tolerability of multiple-dose intravitreal injections of rhuFab V2 in subjects with neovascular age-related macular degeneration who have completed the treatment phase of a Genentech-sponsored phase I or phase I/II rhuFab V2 study

**Sponsor: Genentech, Inc**

GENENTECH(FVF3426g)

(HORIZON) An open-label, multicenter extension study to evaluate the safety and tolerability of Ranibizumab in subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) who have completed the treatment phase of a Genentech-sponsored Ranibizumab study

**Sponsor: Genentech, Inc**

GENENTECH (FVF2587g)

(ANCHOR) A Phase III, multicenter, randomized, double-masked active treatment-controlled study of the efficacy and safety of rhuFab V2 (Ranibizumab) compared to Verteporfin (Visudyne) photodynamic therapy in subjects with predominantly classic subfoveal neovascular age-related macular degeneration

**Sponsor: Genentech, Inc**

GENENTECH (FVF 2598g)

(MARINA) A Phase III, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) in Subjects with Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration

**Sponsor: Genentech, Inc**

GENENTECH (FVF3689g)

(SAILOR) A phase IIIb, Multicenter

study to evaluate the safety and tolerability of Ranibizumab in naïve and previously treated subjects with choroidal neovascularization (CNV) secondary to age-related Macular Degeneration (AMD).

**Sponsor: Genentech, Inc**

Quark (QRK003)

A phase I open-label, dose escalation trial of REDD14NP delivered by a single intravitreal injection to patients with choroidal neovascularization (CNV) secondary to exudative age-related macular degeneration (“Wet AMD”)

**Sponsor: Quark Biotech Inc. and Pfizer Inc.**

POTENTIA (POT-CP-1006)

Assessment of Safety of Intravitreal POT-4 Therapy for Patients with Neovascular Age-Related Macular Degeneration (AMD)

**SPONSOR: Potentia Pharmaceuticals, Inc.**

PRONTO (FVF3102)

A Prospective Optical Coherence Tomography (OCT) imaging of patients with neovascular age-related macular degeneration (AMD) treated with intra-ocular Lucentis™ (Ranibizumab): PrONTO

**Sponsor: Philip J Rosenfeld, MD, PhD**